• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.

    5/22/26 4:05:20 PM ET
    $ACOG
    Get the next $ACOG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Alpha Cognition Inc.

    (Name of Issuer)


    Common Stock, no par value

    (Title of Class of Securities)




    02074J501

    (CUSIP Number)
    05/21/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    02074J501


    1Names of Reporting Persons

    Opaleye Management Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,620,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,620,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,620,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.03 %
    12Type of Reporting Person (See Instructions)

    IA, CO

    Comment for Type of Reporting Person:  Includes shares held in a managed account over which the Adviser has shared voting and dispositive power.


    SCHEDULE 13G

    CUSIP Number(s):
    02074J501


    1Names of Reporting Persons

    Opaleye, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,530,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,530,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,530,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.62 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Based on 21,774,104 shares of common stock outstanding as reported by Alpha Cognition Inc. in its Form 10-Q filed with the SEC on 05/14/2026.


    SCHEDULE 13G

    CUSIP Number(s):
    02074J501


    1Names of Reporting Persons

    James Silverman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,620,369.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,620,369.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,620,369.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.03 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Includes shares held in a managed account over which the Adviser has shared voting and dispositive power.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Alpha Cognition Inc.
    (b)Address of issuer's principal executive offices:

    1452 Hughes Rd. Ste. 200, Grapevine, TX 76051
    Item 2. 
    (a)Name of person filing:

    This statement is filed jointly by (i) Opaleye Management Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund"), and (iii) James Silverman (collectively, the "Reporting Persons") with respect to shares of common stock held directly by the Fund and in a managed account advised by the Adviser. The Adviser serves as investment adviser to the Fund. Mr. Silverman is the controlling person of the Adviser. The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any of the shares reported herein.
    (b)Address or principal business office or, if none, residence:

    One Boston Place, 26th Floor, Boston, MA 02108
    (c)Citizenship:

    Opaleye Management Inc., Massachusetts, Opaleye, L.P., Delaware, James Silverman, USA
    (d)Title of class of securities:

    Common Stock, no par value
    (e)CUSIP No.:

    02074J501
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,620,369.00
    (b)Percent of class:

    12.03 %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    2,620,369.00

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    2,620,369.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Opaleye Management Inc.
     
    Signature:/s/ James Silverman
    Name/Title:President
    Date:05/22/2026
     
    Opaleye, L.P.
     
    Signature:/s/ James Silverman
    Name/Title:General Partner
    Date:05/22/2026
     
    James Silverman
     
    Signature:/s/ James Silverman
    Name/Title:Individually
    Date:05/22/2026
    Exhibit Information

    Exhibit 99.1 Joint Filing Agreement by and among the reporting persons

    Get the next $ACOG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOG

    DatePrice TargetRatingAnalyst
    5/29/2026$12.00Buy
    Maxim Group
    4/17/2026$14.00Buy
    Craig Hallum
    3/18/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.

    SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

    5/22/26 4:05:20 PM ET
    $ACOG

    SEC Form 10-Q filed by Alpha Cognition Inc.

    10-Q - Alpha Cognition Inc. (0001655923) (Filer)

    5/14/26 4:01:44 PM ET
    $ACOG

    Amendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.

    SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

    5/12/26 7:11:10 PM ET
    $ACOG

    $ACOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $434,714 worth of shares (73,738 units at $5.90) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/29/26 7:21:38 PM ET
    $ACOG

    Large owner Opaleye Management Inc. bought $140,545 worth of shares (24,376 units at $5.77) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/22/26 4:05:27 PM ET
    $ACOG

    Chief Operating Officer D'Angelo Lauren bought $20,160 worth of shares (3,500 units at $5.76), increasing direct ownership by 3% to 140,695 units (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/19/26 5:02:16 PM ET
    $ACOG

    $ACOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $434,714 worth of shares (73,738 units at $5.90) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/29/26 7:21:38 PM ET
    $ACOG

    Large owner Opaleye Management Inc. bought $140,545 worth of shares (24,376 units at $5.77) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/22/26 4:05:27 PM ET
    $ACOG

    Chief Operating Officer D'Angelo Lauren bought $20,160 worth of shares (3,500 units at $5.76), increasing direct ownership by 3% to 140,695 units (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/19/26 5:02:16 PM ET
    $ACOG

    $ACOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

    ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan

    5/14/26 4:15:00 PM ET
    $ACOG

    Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

    Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management

    4/28/26 4:30:00 PM ET
    $ACOG

    Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

    Alpha Cognition, Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2:40 p.m. ET H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq Format: Fireside Chat and 1x1 meetings Date/Time: Tuesday, May 19 at 4:30 p.m. ET Craig Hallum's 23rd Annual Institutional Investor Conference Format: 1x1 meetings Date: May 28,

    4/27/26 8:00:00 AM ET
    $ACOG

    $ACOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Alpha Cognition with a new price target

    Maxim Group initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $12.00

    5/29/26 7:48:09 AM ET
    $ACOG

    Craig Hallum initiated coverage on Alpha Cognition with a new price target

    Craig Hallum initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $14.00

    4/17/26 8:03:30 AM ET
    $ACOG

    H.C. Wainwright initiated coverage on Alpha Cognition with a new price target

    H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

    3/18/25 7:48:36 AM ET
    $ACOG

    $ACOG
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro

    4/20/26 5:00:00 PM ET
    $ACOG
    $KALV
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

    4/10/25 8:30:00 AM ET
    $ACOG
    $CBAY
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

    1/14/25 8:30:00 AM ET
    $ACOG

    $ACOG
    Financials

    Live finance-specific insights

    View All

    Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

    ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan

    5/14/26 4:15:00 PM ET
    $ACOG

    Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

    Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management

    4/28/26 4:30:00 PM ET
    $ACOG

    Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

    Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million Fourth quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch Executed second national PBM contract and initiating three studies to further support ZUNVEYL's positioning in long-term care Alzheimer's patients Cash and cash equivalents totaled $66 million at year-end 2025, supporting the company's continued target of operating profitability in 2027 Company to host conference call and webcast today, March 26, at 4:30 p.m. ET Alpha Cognition Inc. (ACOG: NASDA

    3/26/26 4:01:00 PM ET
    $ACOG